Business context and reporting period
Issuer discrepancy: The request identifies PDS Biotechnology Corp., but the supplied Form 10-Q is for Edge Therapeutics, Inc. for the quarter ended September 30, 2015. The summary below covers the filing provided; confirm the intended issuer before relying on it.
Edge was a clinical-stage biotechnology company developing hospital-based therapies for acute neurological conditions using its Precisa drug-delivery platform. It had no approved products and generated no product revenue. The filing compares the three and nine months ended September 30, 2015 with the corresponding 2014 periods.
Financial performance and position
| Metric | Q3 2015 | Q3 2014 | Nine months 2015 | Nine months 2014 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development expense | $6.51 million | $2.42 million | $12.57 million | $5.64 million |
| General and administrative expense | $1.98 million | $1.14 million | $5.05 million | $3.54 million |
| Total operating expenses | $8.48 million | $3.56 million | $17.63 million | $9.18 million |
| Net loss | $10.13 million | $3.52 million | $20.12 million | $9.04 million |
| Net loss attributable to common stockholders | $11.96 million | $3.88 million | $24.38 million | $10.12 million |
| Net cash used in operating activities | Not provided quarterly | $14.97 million | $6.83 million |
Gross margin is not applicable because the company reported no revenue. Loss per share attributable to common stockholders was $7.08 for Q3 and $14.44 for the nine-month period in 2015, versus $2.30 and $5.99, respectively, in 2014. The gap between net loss and common-stockholder loss reflects cumulative preferred dividends.
At September 30, 2015, cash and cash equivalents were $52.88 million, versus $13.73 million at December 31, 2014. Current assets were $55.60 million and current liabilities were $8.45 million. Debt carrying value totaled approximately $5.90 million ($2.21 million short-term and $3.69 million long-term). The company reported an accumulated deficit of $54.20 million. It had no product-sales cash flow; nine-month investing cash use was $0.80 million, primarily for property and equipment.
Material changes and unusual items
- Q3 operating expenses rose 138% year over year; nine-month expenses rose 92%. Management attributed the increases primarily to EG-1962 trial spending, EG-1964 development, and added personnel and public-company-related costs.
- Warrant remeasurement produced a $1.43 million expense in Q3 and $1.88 million for the nine months, compared with gains in the 2014 periods. The remeasurement was a noncash fair-value item.
- Nine-month financing cash flow included $52.39 million net proceeds from a Series C-2 preferred-stock financing and $3.00 million of debt proceeds.
- After quarter-end, on October 6, the company completed an IPO of 8,412,423 shares at $11.00 per share, raising $92.5 million gross and approximately $83.2 million net. Preferred stock converted into 18,566,856 common shares at closing. The September 30 balance sheet does not reflect the IPO or conversion.
- A 1-for-1.3681 reverse stock split occurred September 21; share and per-share figures in the filing were retroactively adjusted.
Outlook, risks and contingencies
Management expected the IPO proceeds together with September 30 cash to fund anticipated requirements for at least 12 months, while cautioning that actual cash use could differ. It expected expenses and operating losses to increase as development advanced, and did not expect product revenue for years. No specific financial guidance was provided.
- EG-1962: following Phase 1/2 NEWTON trial results and FDA end-of-Phase-2 correspondence, the company planned a Phase 3 program for aneurysmal subarachnoid hemorrhage, targeted to begin in mid-2016 subject to FDA review of the final protocol.
- EG-1964: management intended to submit an IND in 2016 and begin a Phase 1/2 trial thereafter for chronic subdural hematoma.
- Key uncertainties include clinical-trial results and costs, FDA requirements (including whether additional Phase 3 trials are needed), regulatory approval, competition, manufacturing and third-party performance, intellectual-property protection, and access to future capital.
- Debt bears a stated base rate of 9.95% after a milestone reduction; principal-and-interest amortization began in October 2015. The loans are secured by substantially all assets other than intellectual property, which is subject to a negative pledge, and include covenants and possible prepayment charges.
- The Evonik license includes up to $14.75 million in development, regulatory and sales milestone payments plus mid-single-digit royalties. These contingent payments were not included in the balance-sheet liabilities or contractual-obligations table because the milestones were not fixed and determinable.
- The company reported no material litigation and no material change to previously disclosed risk factors. Management concluded disclosure controls were effective at a reasonable-assurance level; the cover page indicated the company had not filed all required Exchange Act reports during the preceding 12 months.
Important facts for investors to verify
- Confirm whether the intended filing is Edge Therapeutics’ 2015 Q3 10-Q or a filing for PDS Biotechnology Corp.
- Check post-IPO cash, share count and dilution against subsequent filings; the reported September 30 cash excludes the IPO proceeds.
- Verify the final FDA-agreed EG-1962 Phase 3 design, start timing and any requirement for additional trials.
- Assess cash runway against clinical-development spending, debt amortization and contingent Evonik milestones and royalties.
- Distinguish recurring operating burn from noncash warrant remeasurement and preferred-stock dividends when evaluating reported losses.